SCHEMBL20911647

SCHEMBL20911647

CN(C)C(=O)c1ccc(-n2cc(-c3ccccc3)c3c(=O)[nH]cnc32)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 7/20 0.70
▸ MAPT P10636 8/20 0.70
▸ LMNA P02545 3/20 0.70
▸ HTT P42858 1/20 0.70
▸ GAA P10253 2/20 0.67
▸ PKM P14618 1/20 0.66
▸ KMT2A Q03164 3/20 0.60
▸ CA12 O43570 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ EGFR P00533 4/20 0.44
▸ KDR P35968 3/20 0.44
▸ ABL1 P00519 2/20 0.44
▸ CDK1 P06493 2/20 0.44
▸ ABL2 P42684 2/20 0.44
▸ TP53 P04637 1/20 0.43
▸ MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20898166 0.88 SRC (0.79) SRCMAPTLMNAHTTGAA
SCHEMBL20912357 0.86 SRC (0.77) SRCMAPTLMNAHTTGAA
SCHEMBL20912356 0.85 SRC (0.70) SRCMAPTLMNAHTTGAA
SCHEMBL25066089 0.83 SRC (1.00) SRCMAPTLMNAHTTGAA
SCHEMBL20911954 0.83 SRC (1.00) SRCMAPTLMNAHTTGAA
SCHEMBL20911955 0.83 MAPT (1.00) SRCMAPTLMNAHTTGAA
SCHEMBL20911903 0.80 SRC (0.82) SRCMAPTLMNAHTTGAA
SCHEMBL20911898 0.80 MAPT (1.00) SRCMAPTLMNAHTTGAA
SCHEMBL20911887 0.80 SRC (0.82) SRCMAPTLMNAHTTGAA
SCHEMBL20912083 0.80 SRC (0.87) SRCMAPTLMNAHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 — — US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 — — US disclosed
US-20200339583-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2020-10-29 — — US disclosed
WO-2019073253-A1 MAP4K4 INHIBITORS IMPERIAL INNOVATIONS LIMITED (GB) 2019-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339583-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K2, MAP4K5 SRC 594/4885MAPT 315/4885LMNA 4334/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 SRC 594/4885MAPT 315/4885LMNA 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback